Abbott India Limited (ABBOTINDIA)

Name: Abbott India Limited (ABBOTINDIA) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-09-20

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products.

Dati chiave

Capitalizzazione di mercato: ₹579 billion
Ricavi (esercizio chiuso a 2026-03-31): ₹69.3B
Utile netto: ₹15.5B
Margine lordo: 46.5%
Margine netto: 22.4%

Vedi grafici interattivi e bilanci completi →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Entrate totali	₹69.3B	₹64.1B	₹58.5B	₹53.5B
Utile lordo	₹32.2B	₹29.0B	₹26.1B	₹23.6B
Risultato Operativo (EBIT)	₹18.2B	₹16.4B	₹14.1B	₹11.5B
Reddito netto	₹15.5B	₹14.1B	₹12.0B	₹9.5B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di ABBOTINDIA. /companies/us/ABBOTINDIA

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.